8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
Mar 26, 2026·SEC
Material company update
Mar 25, 2026·SEC
Nkarta, Inc.(NKTX)Earnings, Financials & Key Ratios
NKTX•NASDAQ
Price updated Jun 19, 2026
AboutNkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.Show more
- Revenue$0
- EBITDA-$112M+5.9%
- Net Income-$104M+4.3%
- EPS (Diluted)-1.41+11.9%
- ROE-28.9%+9.5%
NKTX Key Insights
Nkarta, Inc. (NKTX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 82 (top 18%)
- ✓Trading at only 0.7x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when NKTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NKTX Price & Volume
Nkarta, Inc. (NKTX) stock price & volume — 10-year historical chart
Loading chart...
NKTX Growth Metrics
Nkarta, Inc. (NKTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM10.18%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM11.26%
Return on Capital
10 Years-35.04%
5 Years-30.81%
3 Years-30.43%
Last Year-28.05%
NKTX Recent Earnings
Nkarta, Inc. (NKTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.37+5.1%
$0.39
Rev
—
—
Q2 2026
Mar 25, 2026Metric
Actual
Est
EPS
$0.37-15.6%
$0.32
Rev
—
—
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.29+9.4%
$0.32
Rev
—
—
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.31+16.2%
$0.37
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.37vs $0.39+5.1% | — |
| Q2 2026 | Mar 25, 2026 | $0.37vs $0.32-15.6% | — |
| Q4 2025 | Nov 10, 2025 | $0.29vs $0.32+9.4% | — |
| Q3 2025 | Aug 12, 2025 | $0.31vs $0.37+16.2% | — |
Based on last 12 quarters of dataView full earnings history →
NKTX Peer Comparison
Nkarta, Inc. (NKTX) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 | |
 CELC | 4.28B | 87.76 | -23.22 | -244.61% | 1.94 | |||
 STTK | 237.12M | 4.95 | -7.07 | -82.52% | -49.87% | -60.73% | 0.02 | |
 IOVA | 1.4B | 3.91 | -3.59 | 60.6% | -123.9% | -50.17% | 0.07 | |
 TCRX | 119.52M | 0.92 | -0.92 | 266.65% | -13.61% | -91.94% | 0.76 | |
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 |
Compare NKTX vs Peers
Nkarta, Inc. (NKTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NKTX Income Statement
Nkarta, Inc. (NKTX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 6.55M | 115.39K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | -98.24% | -100% | - | - | - | - | - | - |
Cost of Goods Sold | 4.25M | 17.22K | 0 | 0 | 0 | 5.87M | 0 | 9.19M | 2.34M |
COGS % of Revenue | 64.92% | 14.92% | - | - | - | - | - | - | - |
Gross Profit | 2.3M▲ 0% | 98.17K▼ 95.7% | 0▼ 100.0% | 0▲ 0% | 0▲ 0% | -5.87M▲ 0% | 0▲ 100.0% | -9.19M▲ 0% | -2.34M▲ 0% |
Gross Margin % | 35.08% | 85.08% | - | - | - | - | - | - | - |
Gross Profit Growth % | - | -95.73% | -100% | - | - | - | 100% | - | - |
Operating Expenses | 6.91M | 22.46M | 51.51M | 86.43M | 118.95M | 125.78M | 128.19M | 112.01M | 113.97M |
OpEx % of Revenue | 105.44% | 19468.66% | - | - | - | - | - | - | - |
Selling, General & Admin | 2.65M | 5.25M | 15.29M | 23.02M | 28.06M | 34.88M | 31.45M | 31.57M | 25.06M |
SG&A % of Revenue | 40.52% | 4547.35% | - | - | - | - | - | - | - |
Research & Development | 4.25M | 17.22M | 36.22M | 63.41M | 90.9M | 90.9M | 96.74M | 90.43M | 88.91M |
R&D % of Revenue | 64.92% | 14921.31% | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -9.98M | 0 |
Operating Income | -356.45K▲ 0% | -22.35M▼ 6169.8% | -51.51M▼ 130.5% | -86.43M▼ 67.8% | -118.95M▼ 37.6% | -131.65M▼ 10.7% | -128.19M▲ 2.6% | -121.21M▲ 5.5% | -116.31M▲ 0% |
Operating Margin % | -5.44% | -19368.66% | - | - | - | - | - | - | - |
Operating Income Growth % | - | -6169.77% | -130.48% | -67.8% | -37.63% | -10.67% | 2.63% | 5.45% | - |
EBITDA | -173.24K | -21.8M | -50.72M | -84.67M | -116.32M | -125.78M | -119.04M | -112.01M | -107.08M |
EBITDA Margin % | -2.64% | -18889.15% | - | - | - | - | - | - | - |
EBITDA Growth % | - | -12481.32% | -132.72% | -66.94% | -37.37% | -8.14% | 5.36% | 5.9% | 12.81% |
D&A (Non-Cash Add-back) | 183.21K | 553.28K | 786K | 1.76M | 2.64M | 5.87M | 9.15M | 9.19M | 9.23M |
EBIT | -274.5K | -20.6M | -51.51M | -86.43M | -118.95M | -126.35M | -128.19M | -121.21M | -110.74M |
Net Interest Income | 81.95K | -169K | 313K | 370K | 0 | 14.11M | 19.32M | 15.49M | 13.96M |
Interest Income | 81.95K | 304K | 313K | 370K | 5.59M | 14.11M | 19.32M | 15.49M | 13.96M |
Interest Expense | 0 | 473K | 0 | 0 | 5.59M | 0 | 0 | 0 | 0 |
Other Income/Expense | 81.95K | 1.27M | -39.85M | 354K | 5.12M | 14.15M | 19.4M | 17.12M | 16.38M |
Pretax Income | -274.5K▲ 0% | -21.08M▼ 7577.8% | -91.36M▼ 333.5% | -86.08M▲ 5.8% | -113.84M▼ 32.3% | -117.5M▼ 3.2% | -108.79M▲ 7.4% | -104.08M▲ 4.3% | -99.93M▲ 0% |
Pretax Margin % | -4.19% | -18265.66% | - | - | - | - | - | - | - |
Income Tax | 0 | 1.81M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | -8.58% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -274.5K▲ 0% | -21.08M▼ 7577.8% | -91.36M▼ 333.5% | -86.08M▲ 5.8% | -113.84M▼ 32.3% | -117.5M▼ 3.2% | -108.79M▲ 7.4% | -104.08M▲ 4.3% | -99.93M▲ 0% |
Net Margin % | -4.19% | -18265.66% | - | - | - | - | - | - | - |
Net Income Growth % | - | -7577.82% | -333.49% | 5.79% | -32.25% | -3.22% | 7.41% | 4.33% | 10.18% |
Net Income (Continuing) | -274.5K | -21.08M | -91.36M | -86.08M | -113.84M | -117.5M | -108.79M | -104.08M | -99.93M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.01▲ 0% | -2.55▼ 46263.6% | -1.59▲ 37.6% | -2.62▼ 64.8% | -2.61▲ 0.4% | -2.40▲ 8.0% | -1.60▲ 33.3% | -1.41▲ 11.9% | -1.35▲ 0% |
EPS Growth % | - | - | 37.65% | -64.78% | 0.38% | 8.05% | 33.33% | 11.88% | 11.26% |
EPS (Basic) | -0.01 | -2.55 | -1.59 | -2.62 | -2.61 | -2.40 | -1.60 | -1.41 | - |
Diluted Shares Outstanding | 50.27M | 8.98M | 31.8M | 32.86M | 43.63M | 49.01M | 67.87M | 73.99M | 74.26M |
Basic Shares Outstanding | 50.27M | 8.98M | 31.8M | 32.86M | 43.63M | 49.01M | 67.87M | 73.99M | 74.26M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
NKTX Balance Sheet
Nkarta, Inc. (NKTX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 8.23M | 37.47M | 318.83M | 245.78M | 360.69M | 253.07M | 273.34M | 282.51M | 235.88M |
Cash & Short-Term Investments | 7.87M | 36.99M | 314.91M | 238.09M | 352.14M | 248.19M | 267.35M | 276.28M | 230.43M |
Cash Only | 7.87M | 20.61M | 96.69M | 60.82M | 37.49M | 31.04M | 27.87M | 39.63M | 27.36M |
Short-Term Investments | 0 | 16.38M | 218.22M | 177.27M | 314.65M | 217.15M | 239.48M | 236.65M | 203.07M |
Accounts Receivable | 150K | 0 | 0 | 0 | 1.3M | 200K | 200K | 2M | 0 |
Days Sales Outstanding | 8.36 | - | - | - | - | - | - | - | - |
Inventory | 117.29K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | 10.07 | - | - | - | - | - | - | - | - |
Other Current Assets | 94.42K | 66.51K | 1.34M | 3.15M | 1.63M | 1.42M | 2.54M | 4.23M | 5.46M |
Total Non-Current Assets | 1.38M | 10.95M | 18.82M | 28.12M | 112.25M | 125.81M | 227.87M | 121.7M | 136.19M |
Property, Plant & Equipment | 1.29M | 10.22M | 17.86M | 24.53M | 107.66M | 119.28M | 110.67M | 101.15M | 98.3M |
Fixed Asset Turnover | 5.09x | 0.01x | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 89.81K | 268.54K | 0 | 0 | 2.74M | 2.74M | 110.39M | 16.11M | 122.71M |
Other Non-Current Assets | 0 | 455.08K | 960K | 3.59M | 1.85M | 3.8M | 6.8M | 4.44M | 4.32M |
Total Assets | 9.61M▲ 0% | 48.41M▲ 404.0% | 337.65M▲ 597.5% | 273.9M▼ 18.9% | 472.94M▲ 72.7% | 378.88M▼ 19.9% | 501.2M▲ 32.3% | 404.21M▼ 19.4% | 372.07M▲ 0% |
Asset Turnover | 0.68x | 0.00x | - | - | - | - | - | - | 0.00x |
Asset Growth % | - | 404.01% | 597.45% | -18.88% | 72.67% | -19.89% | 32.28% | -19.35% | -79.08% |
Total Current Liabilities | 2.08M | 8.21M | 8.83M | 12.94M | 22.05M | 23.33M | 18.92M | 22.27M | 18.21M |
Accounts Payable | 367.17K | 1.88M | 1.18M | 1.11M | 1.76M | 3.67M | 638K | 2.09M | 1.59M |
Days Payables Outstanding | 31.52 | 39.9K | - | - | - | 227.93 | - | 82.94 | 258.23 |
Short-Term Debt | 0 | 0 | 0 | 0 | 4.25M | 0 | 0 | 6.89M | 7.08M |
Deferred Revenue (Current) | 0 | 2.7M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 408.44K | -857.45K | 117K | 96K | 9.35M | 6.72M | 254K | 13.29M | 9.54M |
Current Ratio | 3.96x | 4.56x | 36.10x | 18.99x | 16.36x | 10.85x | 14.45x | 12.69x | 12.96x |
Quick Ratio | 3.91x | 4.56x | 36.10x | 18.99x | 16.36x | 10.85x | 14.45x | 12.69x | 12.96x |
Cash Conversion Cycle | -13.09 | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 12.92M | 65.68M | 7.6M | 9.99M | 78.69M | 82.27M | 74.31M | 69.62M | 68.01M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 67.92M |
Capital Lease Obligations | 0 | 5.78M | 7.52M | 9.97M | 78.69M | 82.27M | 74.22M | 69.53M | 211.42M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 12.92M | 59.9M | 82K | 18K | 0 | 0 | 87K | 87K | 87K |
Total Liabilities | 15M | 73.89M | 16.43M | 22.94M | 100.73M | 105.6M | 93.23M | 91.88M | 86.21M |
Total Debt | 12.71M | 7.3M | 8.92M | 12.46M | 82.93M | 88.34M | 80.27M | 76.42M | 75M |
Net Debt | 4.84M | -13.31M | -87.77M | -48.36M | 45.44M | 57.3M | 52.4M | 36.79M | 47.64M |
Debt / Equity | - | - | 0.03x | 0.05x | 0.22x | 0.32x | 0.20x | 0.24x | 0.26x |
Debt / EBITDA | - | - | - | - | - | - | - | - | -0.70x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | -0.44x |
Interest Coverage | - | -43.56x | - | - | -21.29x | - | - | - | - |
Total Equity | -5.4M▲ 0% | -25.48M▼ 372.2% | 321.22M▲ 1360.6% | 250.97M▼ 21.9% | 372.21M▲ 48.3% | 273.29M▼ 26.6% | 407.98M▲ 49.3% | 312.32M▼ 23.4% | 285.86M▲ 0% |
Equity Growth % | - | -372.25% | 1360.55% | -21.87% | 48.31% | -26.58% | 49.29% | -23.45% | -90.64% |
Book Value per Share | -0.11 | -2.84 | 10.10 | 7.64 | 8.53 | 5.58 | 6.01 | 4.22 | 3.85 |
Total Shareholders' Equity | -5.4M | -25.48M | 321.22M | 250.97M | 372.21M | 273.29M | 407.98M | 312.32M | 285.86M |
Common Stock | 123 | 160 | 3K | 3K | 5K | 5K | 7K | 7K | 7K |
Retained Earnings | -5.58M | -26.66M | -118.02M | -204.1M | -317.93M | -435.43M | -544.22M | -648.31M | -676.14M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -244.75K | -2.14K | 3K | -150K | -679K | 8K | 674K | 407K | -130K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NKTX Cash Flow Statement
Nkarta, Inc. (NKTX) cash flow — operating, investing & free cash flow history
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -5.18M | -18.37M | -43.51M | -67.93M | -57M | -86.16M | -99.7M | -88.7M | -87.29M |
Operating CF Margin % | -79.14% | -15918.01% | - | - | - | - | - | - | - |
Operating CF Growth % | - | -254.31% | -136.87% | -56.13% | 16.09% | -51.16% | -15.71% | 11.03% | 55.53% |
Net Income | -274.5K | -21.08M | -91.36M | -86.08M | -113.84M | -117.5M | -108.79M | -104.08M | -99.93M |
Depreciation & Amortization | 183.21K | 401K | 786K | 1.76M | 2.64M | 5.87M | 2.24M | 4.61M | 8.74M |
Stock-Based Compensation | 182.51K | 947K | 6.75M | 14.46M | 16.86M | 17.2M | 16.73M | 8.56M | 5.72M |
Deferred Taxes | 0 | 0 | 738K | 3.24M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 548.94K | -818K | 40.41M | 337K | 3.61M | -2.65M | 2.29M | 2.65M | 1.34M |
Working Capital Changes | -5.28M | 2.18M | -828K | -1.64M | 33.74M | 10.93M | -12.16M | -435K | -3.15M |
Change in Receivables | -14.82K | -463.26K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 689.71K | 2.64M | 2.82M | 2.79M | 2.76M | 4.22M | -4.47M | 2.46M | 2.27M |
Cash from Investing | -757.88K | -18.3M | -210.08M | 32.53M | -184.69M | 79.02M | -129.56M | 100.32M | 61.9M |
Capital Expenditures | -757.88K | -1.93M | -7.51M | -5.03M | -47.11M | -28.15M | -4.41M | -1.21M | -1.1M |
CapEx % of Revenue | 11.57% | 1670.93% | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 202.57K | -37.56K | 137.58K | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | -202.57K | 37.56K | -137.58K | 0 | 0 | 0 | 0 |
Cash from Financing | 87.49K | 49.58M | 329.82M | 1.2M | 219.01M | 691K | 226.08M | 141K | 147K |
Debt Issued (Net) | 0 | 49.53M | 64.32M | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 43.55M | 329.42M | 1.2M | 217.17M | 691K | 225.07M | 141K | 147K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 87.49K | -43.5M | -63.92M | 0 | 1.84M | 0 | 1.01M | 0 | 0 |
Net Change in Cash | -5.85M▲ 0% | 12.92M▲ 320.7% | 76.23M▲ 490.1% | -34.19M▼ 144.9% | -22.68M▲ 33.7% | -6.45M▲ 71.5% | -3.17M▲ 50.9% | 11.76M▲ 471.4% | -25.24M▲ 0% |
Free Cash Flow | -5.94M▲ 0% | -20.3M▼ 241.6% | -51.02M▼ 151.4% | -72.95M▼ 43.0% | -104.11M▼ 42.7% | -114.31M▼ 9.8% | -104.11M▲ 8.9% | -89.91M▲ 13.6% | -88.39M▲ 0% |
FCF Margin % | -90.71% | -17588.94% | - | - | - | - | - | - | - |
FCF Growth % | - | -241.56% | -151.38% | -43% | -42.71% | -9.79% | 8.93% | 13.64% | 16.26% |
FCF per Share | -0.12 | -2.26 | -1.60 | -2.22 | -2.39 | -2.33 | -1.53 | -1.22 | -1.19 |
FCF Conversion (FCF/Net Income) | 18.88x | 0.87x | 0.48x | 0.79x | 0.50x | 0.73x | 0.92x | 0.85x | 0.88x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NKTX Key Ratios
Nkarta, Inc. (NKTX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -61.79% | -30.09% | -36.53% | -36.41% | -31.94% | -28.9% | -30.9% |
Return on Invested Capital (ROIC) | - | -39.69% | -29.73% | -28.77% | -26.39% | -24.31% | -22.46% | -24.58% |
Gross Margin | 85.08% | - | - | - | - | - | - | - |
Net Margin | -18265.66% | - | - | - | - | - | - | - |
Debt / Equity | - | 0.03x | 0.05x | 0.22x | 0.32x | 0.20x | 0.24x | 0.26x |
Interest Coverage | -43.56x | - | - | -21.29x | - | - | - | - |
FCF Conversion | 0.87x | 0.48x | 0.79x | 0.50x | 0.73x | 0.92x | 0.85x | 0.88x |
Revenue Growth | -98.24% | -100% | - | - | - | - | - | - |
Related:NKTX Dividend History·NKTX Revenue History·NKTX Price History·NKTX P/E History·NKTX Financial Ratios·NKTX Institutional Holders
NKTX SEC Filings & Documents
Nkarta, Inc. (NKTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
NKTX Frequently Asked Questions
Nkarta, Inc. (NKTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Nkarta, Inc. (NKTX) grew revenue by 0.0% over the past year. Growth has been modest.
Nkarta, Inc. (NKTX) reported a net loss of $99.9M for fiscal year 2025.
Dividend & Returns
Nkarta, Inc. (NKTX) has a return on equity (ROE) of -28.9%. Negative ROE indicates the company is unprofitable.
Nkarta, Inc. (NKTX) had negative free cash flow of $88.4M in fiscal year 2025, likely due to heavy capital investments.